Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
542 questions in 42 reviews · Skin
current versionsNo studies 542 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Nicotinamide vs erythromycin Participants' global self‐assessment of acne improvement · participants with acne Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha‐hydroxy acid) for acne (2020) · Cochrane | no estimate extracted | NR | No studies |
Nicotinamide vs erythromycin Total number of participants who experienced at least one minor adverse event · participants with acne Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha‐hydroxy acid) for acne (2020) · Cochrane | no estimate extracted | NR | No studies |
Nicotinamide vs erythromycin Quality of life · participants with acne Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha‐hydroxy acid) for acne (2020) · Cochrane | no estimate extracted | NR | No studies |
Glycolic acid (alpha‐hydroxy acid) vs salicylic‐mandelic acid Quality of life · participants with acne Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha‐hydroxy acid) for acne (2020) · Cochrane | no estimate extracted | NR | No studies |
Azelaic acid vs benzoyl peroxide Quality of life · participants with acne Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha‐hydroxy acid) for acne (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Erythema · people 60 years of age and older Hygiene and emollient interventions for maintaining skin integrity in older people in hospital and… (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Clinical score of itch · people 60 years of age and older Hygiene and emollient interventions for maintaining skin integrity in older people in hospital and… (2020) · Cochrane | no estimate extracted | NR | No studies |
Topical vitamin D derivative vs placebo Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Topical vitamin D derivative vs placebo Proportion of participants achieving a 50% reduction in disease severity ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Topical vitamin D derivative vs placebo Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Topical vitamin D derivative vs placebo Ease of compliance to an intervention or a treatment ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Puvatherapy vs placebo or no treatment Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Puvatherapy vs placebo or no treatment Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Puvatherapy vs placebo or no treatment Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Triamcinolone acetonide 0.1% cream with occlusive dressing vs clobetasol cream 0.05% cream Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · for chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Puvatherapy vs placebo or no treatment Ease of compliance to an intervention or a treatment ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
UVA1 vs narrowband UVB Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
UVA1 vs narrowband UVB Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
UVA1 vs narrowband UVB Proportion of participants achieving a 50% reduction in disease severity ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
UVA1 vs narrowband UVB Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
UVA1 vs narrowband UVB Ease of compliance to an intervention or a treatment ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Triamcinolone acetonide 0.1% cream with occlusive dressing vs clobetasol cream 0.05% cream Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · for chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etretinate vs placebo or no treatment Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etretinate vs placebo or no treatment Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etretinate vs placebo or no treatment Proportion of participants achieving a 50% reduction in disease severity ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etretinate vs placebo or no treatment Ease of compliance to an intervention or a treatment ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etretinate with PUVA therapy as co‐intervention vs placebo with PUVA therapy Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etretinate with PUVA therapy as co‐intervention vs placebo with PUVA therapy Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etretinate with PUVA therapy as co‐intervention vs placebo with PUVA therapy Proportion of participants achieving a 50% reduction in disease severity ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Triamcinolone acetonide 0.1% cream with occlusive dressing vs clobetasol cream 0.05% cream Proportion of participants achieving a 50% reduction in disease severity ‐ not reported · for chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etretinate with PUVA therapy as co‐intervention vs placebo with PUVA therapy Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etretinate with PUVA therapy as co‐intervention vs placebo with PUVA therapy Ease of compliance to an intervention or a treatment ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etretinate vs PUVA therapy Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etretinate vs PUVA therapy Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etretinate vs PUVA therapy Proportion of participants achieving a 50% reduction in disease severity ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etretinate vs PUVA therapy Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etretinate vs PUVA therapy Ease of compliance to an intervention or a treatment ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Triamcinolone acetonide 0.1% cream with occlusive dressing vs clobetasol cream 0.05% cream Proportion of participants without relapse in the long term ‐ not reported · for chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Alitretinoin vs placebo Proportion of participants cleared or almost cleared ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Alitretinoin vs placebo Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Alitretinoin vs placebo Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Alitretinoin vs placebo Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Alitretinoin vs placebo Ease of compliance to an intervention or a treatment ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs placebo Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs placebo Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs placebo Proportion of participants achieving a 50% reduction in disease severity ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs placebo Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs placebo Proportion of participants with adverse effects ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs placebo Ease of compliance to an intervention or a treatment ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Ustekinumab vs placebo Proportion of participants cleared or almost cleared ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |